RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIA Pharmaceuticals Stock

VIA Pharmaceuticals EBIT 2024

VIA Pharmaceuticals EBIT

0 USD

Ticker

VIAP

ISIN

US92554T1034

In 2024, VIA Pharmaceuticals's EBIT was 0 USD, a -100% increase from the -5.91 M USD EBIT recorded in the previous year.

The VIA Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2011e-
2010-
2009-
2008-
2007-
2006-
2005-
2004-
2003-
2002-
2001-
2000-
1999-
1998-
1997-
1996-

VIA Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VIA Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VIA Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VIA Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VIA Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VIA Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VIA Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VIA Pharmaceuticals’s growth potential.

VIA Pharmaceuticals Revenue, EBIT and net profit per share

DateVIA Pharmaceuticals RevenueVIA Pharmaceuticals EBITVIA Pharmaceuticals Net Income
2011e-9,291.51 TT undefined0 undefined0 undefined
20100 undefined-5.91 M undefined-9.6 M undefined
20090 undefined-13.25 M undefined-20.98 M undefined
20080 undefined-20.46 M undefined-20.27 M undefined
20070 undefined-18.53 M undefined-21.84 M undefined
20060 undefined-8.22 M undefined-8.63 M undefined
200583,000 undefined-19.76 M undefined-19.74 M undefined
200480,000 undefined-10.19 M undefined-10.38 M undefined
200340,000 undefined-11.12 M undefined-30.41 M undefined
20021.12 M undefined-11.62 M undefined-12.05 M undefined
2001300,000 undefined-11.86 M undefined-11.1 M undefined
2000160,000 undefined-8.62 M undefined-9.61 M undefined
1999120,000 undefined-3.41 M undefined-3.82 M undefined
1998190,000 undefined-2.21 M undefined-7.96 M undefined
1997190,000 undefined-300,000 undefined-300,000 undefined
19960 undefined-520,000 undefined-440,000 undefined

VIA Pharmaceuticals stock margins

The VIA Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VIA Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VIA Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VIA Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the VIA Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VIA Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VIA Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VIA Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VIA Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VIA Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VIA Pharmaceuticals Margin History

VIA Pharmaceuticals Gross marginVIA Pharmaceuticals Profit marginVIA Pharmaceuticals EBIT marginVIA Pharmaceuticals Profit margin
2011e100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %-23,810.84 %-23,778.31 %
2004100 %-12,737.5 %-12,975 %
2003100 %-27,800 %-76,025 %
2002100 %-1,037.5 %-1,075.89 %
2001100 %-3,953.33 %-3,700 %
2000100 %-5,387.5 %-6,006.25 %
1999100 %-2,841.67 %-3,183.33 %
1998100 %-1,163.16 %-4,189.47 %
1997100 %-157.89 %-157.89 %
1996100 %0 %0 %

VIA Pharmaceuticals Aktienanalyse

What does VIA Pharmaceuticals do?

VIA Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company was founded in 1999 in San Francisco. The vision of VIA Pharmaceuticals from the beginning was to develop more innovative therapies for the treatment of cardiovascular diseases that are more effective and have fewer side effects compared to existing treatment options. The company focuses on the discovery and exploration of new active substances and technologies that target the causes of cardiovascular diseases. VIA Pharmaceuticals' business model is based on collaboration with other biopharmaceutical companies and research institutes. For example, the company collaborates with the Cleveland Clinic and the University of California to advance the development of new drugs. Collaboration with investors and financial institutions also plays an important role in VIA Pharmaceuticals' business model. The various divisions of VIA Pharmaceuticals specialize in the treatment of cardiovascular diseases. In particular, drugs for the treatment of atherosclerosis, one of the main causes of cardiovascular diseases, are being developed. VIA Pharmaceuticals' research focuses on reducing inflammation and blood lipids. The products of VIA Pharmaceuticals are currently still in clinical development. One of the most promising products of the company is VIA-2291, a drug for the treatment of atherosclerosis. The drug specifically targets inflammation in blood vessels, reducing the risk of plaques and thrombosis. VIA-2291 has already shown promising results in clinical trials and is currently in phase 3 of clinical development. Other products of VIA Pharmaceuticals are in various stages of clinical development. Overall, VIA Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company relies on collaboration with other research institutes and biotech companies. The products of VIA Pharmaceuticals are currently still in clinical development but show promising results and could contribute to making the treatment of cardiovascular diseases more effective and with fewer side effects in the future. VIA Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing VIA Pharmaceuticals's EBIT

VIA Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of VIA Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

VIA Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in VIA Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about VIA Pharmaceuticals stock

How much did VIA Pharmaceuticals achieve in EBIT for the current year?

In the current year, VIA Pharmaceuticals has achieved an EBIT of 0 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company VIA Pharmaceuticals.

How has the EBIT of VIA Pharmaceuticals developed in recent years?

The EBIT of VIA Pharmaceuticals has increased by -100% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company VIA Pharmaceuticals?

The EBIT of VIA Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does VIA Pharmaceuticals pay?

Over the past 12 months, VIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of VIA Pharmaceuticals?

The current dividend yield of VIA Pharmaceuticals is .

When does VIA Pharmaceuticals pay dividends?

VIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VIA Pharmaceuticals?

VIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of VIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIA Pharmaceuticals located?

VIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIA Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did VIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of VIA Pharmaceuticals in the year 2023?

In the year 2023, VIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does VIA Pharmaceuticals pay out the dividend?

The dividends of VIA Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIA Pharmaceuticals

Our stock analysis for VIA Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIA Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.